X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (862) 862
Publication (80) 80
Book Review (22) 22
Book Chapter (5) 5
Conference Proceeding (4) 4
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (725) 725
index medicus (487) 487
female (429) 429
male (419) 419
androstenes - administration & dosage (360) 360
adult (265) 265
androstenes - therapeutic use (191) 191
middle aged (190) 190
drospirenone (186) 186
androstenes - pharmacology (180) 180
animals (180) 180
androstenes - adverse effects (177) 177
obstetrics & gynecology (176) 176
ethinyl estradiol - administration & dosage (158) 158
treatment outcome (155) 155
prostate cancer (154) 154
prostatic neoplasms, castration-resistant - drug therapy (148) 148
aged (135) 135
androstenes (135) 135
oncology (134) 134
adolescent (122) 122
abiraterone (112) 112
phenylthiohydantoin - analogs & derivatives (106) 106
prostatic neoplasms - drug therapy (106) 106
young adult (104) 104
urology & nephrology (101) 101
women (97) 97
abiraterone acetate (92) 92
contraceptives, oral, combined - administration & dosage (92) 92
docetaxel (92) 92
oral contraceptives (90) 90
chemotherapy (89) 89
endocrinology & metabolism (89) 89
prostatic neoplasms, castration-resistant - pathology (87) 87
ethinyl estradiol (86) 86
enzalutamide (81) 81
contraceptives, oral, combined - adverse effects (77) 77
ethinyl estradiol - adverse effects (77) 77
obstetrics and gynecology (76) 76
metastasis (74) 74
increased survival (72) 72
antineoplastic combined chemotherapy protocols - therapeutic use (71) 71
androstenols - therapeutic use (70) 70
pharmacology & pharmacy (70) 70
antineoplastic agents - therapeutic use (67) 67
rats (67) 67
aged, 80 and over (66) 66
mineralocorticoid receptor antagonists - administration & dosage (66) 66
analysis (65) 65
cancer (65) 65
prospective studies (63) 63
dose-response relationship, drug (62) 62
drug administration schedule (62) 62
estradiol (62) 62
care and treatment (61) 61
phenylthiohydantoin - therapeutic use (61) 61
risk factors (60) 60
testosterone (59) 59
drug therapy, combination (57) 57
taxoids - therapeutic use (56) 56
androgen antagonists - therapeutic use (55) 55
disease-free survival (53) 53
estradiol - administration & dosage (53) 53
neoplasm metastasis (53) 53
retrospective studies (53) 53
health aspects (52) 52
androgens (51) 51
double-blind method (51) 51
ethinylestradiol (51) 51
prostatic neoplasms - pathology (51) 51
research (51) 51
taxoids - administration & dosage (51) 51
castration (49) 49
postmenopausal women (49) 49
drug therapy (48) 48
estrogens - administration & dosage (48) 48
mice (48) 48
testosterone - blood (48) 48
drug combinations (47) 47
androstenes - metabolism (46) 46
biochemistry & molecular biology (46) 46
double-blind (46) 46
ethinyl estradiol - therapeutic use (46) 46
prednisone (46) 46
pregnancy (46) 46
prostate-specific antigen - blood (46) 46
urology (46) 46
administration, oral (45) 45
efficacy (45) 45
survival (45) 45
time factors (45) 45
acetate (44) 44
androgen receptor (44) 44
estrogen (44) 44
antitumor-activity (43) 43
castration-resistant prostate cancer (43) 43
disease progression (43) 43
finasteride (43) 43
mineralocorticoid receptor antagonists - adverse effects (43) 43
5-alpha reductase inhibitors (42) 42
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (818) 818
German (15) 15
French (7) 7
Italian (7) 7
Chinese (3) 3
Russian (3) 3
Bulgarian (2) 2
Hungarian (2) 2
Japanese (2) 2
Polish (2) 2
Spanish (2) 2
Finnish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0182045
Combined estrogen-progestin preparations (CEPs) are associated with thromboembolic (TE) side effects. The aim of this study was to evaluate the incidence of TE... 
HORMONAL CONTRACEPTION | SYSTEM DATABASE | SIGNAL-DETECTION | VENOUS THROMBOEMBOLISM | MYOCARDIAL-INFARCTION | THROMBOSIS | ODDS RATIO | MULTIDISCIPLINARY SCIENCES | ORAL-CONTRACEPTIVE USE | SWEDISH WOMEN | RISK | Norgestrel - administration & dosage | Thromboembolism - chemically induced | Desogestrel - adverse effects | Humans | Middle Aged | Progestins - adverse effects | Male | Norgestrel - adverse effects | Estrogens - adverse effects | Norethindrone - administration & dosage | Young Adult | Ethinyl Estradiol - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Norethindrone - adverse effects | Adult | Female | Ethinyl Estradiol - administration & dosage | Contraceptives, Oral, Combined - administration & dosage | Odds Ratio | Child | Databases, Factual | Androstenes - adverse effects | Adverse Drug Reaction Reporting Systems | Japan | Androstenes - administration & dosage | Contraceptives, Oral, Combined - adverse effects | Desogestrel - administration & dosage | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Progestins - administration & dosage | Adolescent | Estrogens - administration & dosage | Progestational hormones | Thromboembolism | Health aspects | Risk factors | Estrogen | Drugs | Ethinylestradiol | Medical equipment | Medical devices | Anemia | Estrogens | Cases (containers) | Risk analysis | Data mining | Patients | Estradiol | Data bases | Incidence | Birth control | Sex hormones | Side effects | Databases | Progestin | Health risk assessment | Pharmaceuticals
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
Journal Article
World Journal of Urology, ISSN 0724-4983, 6/2015, Volume 33, Issue 6, pp. 833 - 839
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 10/2012, Volume 72, Issue 14, pp. 1917 - 1928
Nomegestrol acetate/estradiol is a combined oral contraceptive with approval in many countries. This fixed-dose combination tablet contains nomegestrol... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Adis-Drug-Profiles | Estradiolnomegestrol | Contraception | Oral-contraceptives | Ethinylestradioldrospirenone | LEVONORGESTREL | EFFICACY | ESTRADIOL | DROSPIRENONE | REGIMEN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ETHINYLESTRADIOL | ACETATE | CARBOHYDRATE-METABOLISM | 17-BETA-ESTRADIOL | OVARIAN-FUNCTION | Humans | Middle Aged | Norpregnadienes - administration & dosage | Estrogens - adverse effects | Young Adult | Ethinyl Estradiol - adverse effects | Megestrol - administration & dosage | Estrogens - chemistry | Contraceptives, Oral, Combined - chemistry | Megestrol - agonists | Megestrol - chemistry | Estradiol - adverse effects | Adult | Female | Acne Vulgaris - chemically induced | Ethinyl Estradiol - administration & dosage | Menstrual Cycle - drug effects | Contraceptives, Oral, Combined - administration & dosage | Drug Therapy, Combination | Progesterone Congeners - adverse effects | Androstenes - adverse effects | Estradiol - administration & dosage | Androstenes - administration & dosage | Contraceptives, Oral, Combined - adverse effects | Randomized Controlled Trials as Topic | Pregnancy | Estradiol - chemistry | Adolescent | Progesterone Congeners - administration & dosage | Progesterone Congeners - chemistry | Norpregnadienes - chemistry | Estrogens - administration & dosage | Norpregnadienes - agonists | Menstruation disorders | Contraceptives | Dosage and administration | Hormone therapy | Drug therapy | Methods
Journal Article
Current Urology Reports, ISSN 1527-2737, 6/2013, Volume 14, Issue 3, pp. 174 - 183
Until 2010, chemotherapy with docetaxel was the only approved agent for treatment of metastatic castrate resistant prostate cancer (mCRPC). Since then, the... 
Optimal sequencing of novel agents | Nephrology | Agents in phase 3 trials | Medicine & Public Health | Urology/Andrology | Abiraterone | Androgen axis inhibitors | Enzalutamide | Sipuleucel-T | Alpharadin (Radium-223) | Metastatic castration resistant prostate cancer | Cabazitaxel | CONTROLLED-TRIAL | MITOXANTRONE | PHASE-II | DOCETAXEL | PREDNISONE | IMMUNOTHERAPY | DOUBLE-BLIND | TASQUINIMOD | UROLOGY & NEPHROLOGY | ABIRATERONE ACETATE | INCREASED SURVIVAL | Radium - administration & dosage | Pyridines - administration & dosage | Tissue Extracts - administration & dosage | Humans | Ipilimumab | Androstenes | Imidazoles - administration & dosage | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Quinolines - administration & dosage | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolones | Disease-Free Survival | Phenylthiohydantoin - administration & dosage | Taxoids - administration & dosage | Thionucleotides - administration & dosage | Anilides - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Naphthalenes - administration & dosage | Radioisotopes - administration & dosage | Androstenols - administration & dosage | Antimitotic agents | Care and treatment | Chemotherapy | Reports | Forecasts and trends | Antineoplastic agents | Prostate cancer | Cancer
Journal Article
Journal of Oral Pathology & Medicine, ISSN 0904-2512, 08/2018, Volume 47, Issue 7, pp. 691 - 695
Journal Article
BMC Research Notes, ISSN 1756-0500, 05/2018, Volume 11, Issue 1, pp. 342 - 5
Journal Article